AstraZeneca returning AOM's ZD0473

AnorMed (TSE:AOM) said that AstraZeneca (AZN; LSE:AZN) will discontinue its development of ZD0473, a platinum-based therapeutic to treat ovarian and lung cancer. AZN said the product did not meet AZN's requirements in patients who have previously failed a platinum therapy. AZN previously announced that it was reevaluating the product based on response rate data in resistant patients (see BioCentury, Sept. 10). ...